News | Clinical Decision Support | March 11, 2015

Point of Care Decision Support Anticoagulation Software Helps Reduce Hospital Re-Admissions

Software is designed and developed in association with national patient safety guidelines to reduce adverse events and re-admissions

Point of Care Decision Support, anticoagulation software, PCDS AC, therapy

Image courtesy of Point of Care Decision Support

March 11, 2015 — Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation (AC) drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.

PCDS AC meets the key recommendations of The Joint Commission, the Centers for Medicare and Medicaid Services (CMS) and the Anticoagulation EHR (Electronic Health Record) Task Force. The system could be beneficial in light of new target-specfic oral anticoagulants (TSOAC) drugs coming onto the market, changing AC therapy protocols and more stringent regulatory guidelines.

Key benefits and outcomes of using PCDS AC include:

Patient Safety and Cost Savings: Warfarin-related adverse drug events (myocardial infarctions, strokes, major bleeds, etc.) are reduced by consistently achieving time-in-therapeutic range (TTR) above 70 percent per CMS recommendations.

Patient Safety & Revenue Generation: The PCDS AC system brings together the ACCP Antithrombotic guidelines, risk ratings like CHA2DS2-VASc, HAS-BLED, HEMORR2HAGES, drug-drug interactions, and other evidence-based research to automatically identify high risk patients and manage their AC care end-to-end.  This also provides an opportunity to identify new patients who may benefit from proactive AC therapy and reduce their overall risk of stroke.

Patient Satisfaction: The PCDS AC system incorporates full TSOAC therapy and workflow, which allow for expanded paradigms of anticoagulant management. These new TSOAC agents require far less blood testing, which is a major benefit for patients.  In addition, the system provides data on the efficacy of TSOACs, leading to improved patient care and, ultimately, cost savings surrounding adverse events.

Fulfill CMS Meaningful Use Stages 2 & 3: Provides ability to fulfill CMS MU-2 criteria for quality of Warfarin dosing at a system level with TTR > 70 percent.  Achieves MU-3 measures by improving population health, provides decision support for high priority health conditions, and provides patient self-management tools via a mobile patient engagement application.

Point of Care Decision Support provides any healthcare organization a free, customized demonstration and business case report for its anticoagulant patient population. 

For more information: www.ptofcare.com

Related Content

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati
Medtronic Cobalt and Crome ICD
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received U.S.
The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time. FDA clears, approved, the HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation.

The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time.

News | EP Lab | May 12, 2020
May 12, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the next-generation CardioFocus Inc.
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to edu